Key Takeaways Novo Nordisk's Ozempic cut major cardiovascular event risk by 23% versus Eli Lilly's Trulicity.Ozempic also showed a 25% reduction in a broader composite endpoint in the REACH study.Novo Nordisk secured EU approval to add cardiovascular benefits to the Rybelsus label.The global GLP-1 market has been in the spotlight for the past couple of years as big pharma players realize its multi-billion-dollar potential and the untapped nature. It is currently dominated by Novo Nordisk (NVO) and Eli Lilly ...